Image
Verda Davis

Our Mission

Improving the health of the older adults in Kentucky and beyond through research dedicated to understanding the aging process and age-related brain diseases, and education, outreach, and clinical programs that promote healthy brain aging.

Image
SB exterior

Drug studied at UK is first disease-modifying therapy in U.S. approved to treat Alzheimer’s

In 2023, the FDA fully approved Leqembi (lecanemab) for Alzheimer’s treatment. UK’s Sanders-Brown Center on Aging has studied this and similar drugs for over a decade.

75%
Increase in Funding
NIH funding to the Sanders-Brown Center on Aging increased from $13.3 million to $23.4 million in one year, a remarkable 75% increase in funding.
125
Employees
Beginning with only three faculty members, the Center has grown to more than 125 employees and to be one of the nation's leading centers on aging.

Learn More

Access the latest information about the Sanders-Brown Center on Aging on social media pages: Facebook   X (formerly Twitter)  YouTube

Listen to Sanders-Brown Center on Aging experts on the Mind Matters podcast on Spotify, Apple, and iHeart Media.